1. Academic Validation
  2. Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors

Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors

  • ACS Med Chem Lett. 2023 Apr 17;14(5):606-613. doi: 10.1021/acsmedchemlett.3c00029.
Dalton R Kim 1 Meghan J Orr 1 Ada J Kwong 1 Kristine K Deibler 1 Hasan H Munshi 1 Cory Seth Bridges 2 Taylor Jie Chen 2 Xiaoyu Zhang 1 3 H Daniel Lacorazza 2 Karl A Scheidt 1 3 4
Affiliations

Affiliations

  • 1 Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
  • 2 Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.
  • 3 Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208, United States.
  • 4 Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.
Abstract

The mitogen-activated protein kinase signaling cascade is conserved across eukaryotes, where it plays a critical role in the regulation of activities including proliferation, differentiation, and stress responses. This pathway propagates external stimuli through a series of phosphorylation events, which allows external signals to influence metabolic and transcriptional activities. Within the cascade, MEK, or MAP2K, Enzymes occupy a molecular crossroads immediately upstream to significant signal divergence and cross-talk. One such kinase, MAP2K7, also known as MEK7 and MKK7, is a protein of great interest in the molecular pathophysiology underlying pediatric T cell acute lymphoblastic leukemia (T-ALL). Herein, we describe the rational design, synthesis, evaluation, and optimization of a novel class of irreversible MAP2K7 inhibitors. With a streamlined one-pot synthesis, favorable in vitro potency and selectivity, and promising cellular activity, this novel class of compounds wields promise as a powerful tool in the study of pediatric T-ALL.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-171178
    MAP2K7抑制剂